国有企业制药公司(PT INDOFARMA案例研究)TBK的财务业绩分析。

Vina Anggita Sari, Mujino Mujino
{"title":"国有企业制药公司(PT INDOFARMA案例研究)TBK的财务业绩分析。","authors":"Vina Anggita Sari, Mujino Mujino","doi":"10.37729/sjmb.v18i2.6845","DOIUrl":null,"url":null,"abstract":"This study aims to determine the financial performance of PT Indofarma (Persero) Tbk. the period 2014 - 2019 whether it is in good condition or not. The method of measuring performance is by assessing the level of health. Based on the Decree of the Minister of State-Owned Enterprises Number: KEP-100 / MBU / 2002 it is focused on the financial aspect, consisting of 8 indicators including; return on equity, return on investment, cash ratio, current ratio, collection periods, inventory turnover, total asset turnover, total equity to total assets. The results of 8 indicators for 2014 - 2019 fluctuated, in 2014 the total score was 37.5 in the BBB category, in 2015 the total score was 42 in the BBB category, in 2016 the total score was 32.5 in the BB category, in 2017 the total score was 32.5 in the BB category, in 2018 the total score was 34.5 in the BB category, and in 2019 the total score was 40.5 in the BBB category. With the results of this assessment, it can be concluded that for 2014-2019 the level of financial health of PT Indofarma (Persero) Tbk. Get the predicate less healthy, because the total score at 6 years <65.","PeriodicalId":212214,"journal":{"name":"SEGMEN: Jurnal Manajemen dan Bisnis","volume":"88 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ANALISIS KINERJA KEUANGAN UNTUK MENILAI KESEHATAN PERUSAHAAN FARMASI MILIK BUMN (STUDI KASUS PT INDOFARMA (PERSERO) TBK.)\",\"authors\":\"Vina Anggita Sari, Mujino Mujino\",\"doi\":\"10.37729/sjmb.v18i2.6845\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This study aims to determine the financial performance of PT Indofarma (Persero) Tbk. the period 2014 - 2019 whether it is in good condition or not. The method of measuring performance is by assessing the level of health. Based on the Decree of the Minister of State-Owned Enterprises Number: KEP-100 / MBU / 2002 it is focused on the financial aspect, consisting of 8 indicators including; return on equity, return on investment, cash ratio, current ratio, collection periods, inventory turnover, total asset turnover, total equity to total assets. The results of 8 indicators for 2014 - 2019 fluctuated, in 2014 the total score was 37.5 in the BBB category, in 2015 the total score was 42 in the BBB category, in 2016 the total score was 32.5 in the BB category, in 2017 the total score was 32.5 in the BB category, in 2018 the total score was 34.5 in the BB category, and in 2019 the total score was 40.5 in the BBB category. With the results of this assessment, it can be concluded that for 2014-2019 the level of financial health of PT Indofarma (Persero) Tbk. Get the predicate less healthy, because the total score at 6 years <65.\",\"PeriodicalId\":212214,\"journal\":{\"name\":\"SEGMEN: Jurnal Manajemen dan Bisnis\",\"volume\":\"88 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SEGMEN: Jurnal Manajemen dan Bisnis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37729/sjmb.v18i2.6845\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SEGMEN: Jurnal Manajemen dan Bisnis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37729/sjmb.v18i2.6845","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在确定PT Indofarma (Persero) Tbk的财务绩效。2014 - 2019年期间是否完好。衡量绩效的方法是评估健康水平。根据第KEP-100 / MBU / 2002号国有企业部长法令,该计划侧重于财政方面,由8项指标组成,包括:净资产收益率,投资收益率,现金比率,流动比率,收款周期,存货周转率,总资产周转率,总权益对总资产的比率。2014 - 2019年8项指标结果波动,2014年BBB类总分为37.5分,2015年BBB类总分为42分,2016年BB类总分为32.5分,2017年BB类总分为32.5分,2018年BB类总分为34.5分,2019年BBB类总分为40.5分。根据本次评估结果,可以得出2014-2019年PT Indofarma (Persero) Tbk的财务健康水平。得到谓词较不健康,因为6岁时的总分<65。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
ANALISIS KINERJA KEUANGAN UNTUK MENILAI KESEHATAN PERUSAHAAN FARMASI MILIK BUMN (STUDI KASUS PT INDOFARMA (PERSERO) TBK.)
This study aims to determine the financial performance of PT Indofarma (Persero) Tbk. the period 2014 - 2019 whether it is in good condition or not. The method of measuring performance is by assessing the level of health. Based on the Decree of the Minister of State-Owned Enterprises Number: KEP-100 / MBU / 2002 it is focused on the financial aspect, consisting of 8 indicators including; return on equity, return on investment, cash ratio, current ratio, collection periods, inventory turnover, total asset turnover, total equity to total assets. The results of 8 indicators for 2014 - 2019 fluctuated, in 2014 the total score was 37.5 in the BBB category, in 2015 the total score was 42 in the BBB category, in 2016 the total score was 32.5 in the BB category, in 2017 the total score was 32.5 in the BB category, in 2018 the total score was 34.5 in the BB category, and in 2019 the total score was 40.5 in the BBB category. With the results of this assessment, it can be concluded that for 2014-2019 the level of financial health of PT Indofarma (Persero) Tbk. Get the predicate less healthy, because the total score at 6 years <65.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信